DiaCarta, MIODx to Codevelop Diagnostic to Predict Immunotherapy Response – GenomeWeb
|
DiaCarta, MIODx to Codevelop Diagnostic to Predict Immunotherapy Response
GenomeWeb NEW YORK (GenomeWeb) – DiaCarta and MIODx today said they plan to codevelop a diagnostic test to predict immunotherapy response based on MIODx’s immune sequencing technology, ClonoMap. The test will be developed and validated at DiaCarta’s CLIA … DiaCarta and MIODx Join Forces to Develop a Diagnostic Test to Predict Patient Responses to ImmunotherapyBusiness Wire (press release) |
Medical Xpress |
Consolidation Immunotherapy in Locally Advanced NSCLC
Targeted Oncology Jyoti Patel, MD: This patient illustrates, really, what I’ve started to do in my practice. For patients who are eligible for checkpoint blockade because they don’t have a history of autoimmune disease, they don’t have HIV, and they’re otherwise well … Researchers find promising treatment strategy for stage 1-3 NSCL cancer patientsMedical Xpress SU2C researchers find promising treatment strategy for stage 1-3 NSCL cancer patientsEurekAlert (press release) |
Business Insider |
Merck, Bristol-Myers immunotherapies impress in key lung cancer trials
Reuters (Reuters) – Merck & Co’s immunotherapy Keytruda plus chemotherapy significantly improved overall survival versus chemotherapy alone in newly-diagnosed patients with advanced non-small cell lung cancer in a highly-anticipated study that appears to … ‘We are going to have lung cancer patients living longer and better’: A new kind of cancer treatment is about to …Business Insider Merck lung cancer trial boosts immunotherapy hopesFinancial Times |
Business Insider UK |
‘We are going to have lung cancer patients living longer and better:’ A new kind of cancer treatment is about to …
Business Insider UK In data presented Monday at the American Association of Cancer Research’s annual meeting, cancer drugmakers showed that the use of immunotherapy in combination with other drugs did a better job of treating lung cancer than chemotherapy alone. The … Adding Merck’s Keytruda To Chemo Halves Death Risk For Lung Cancer PatientsForbes |
Telegraph.co.uk |
Immunotherapy-first cancer treatment a ‘game-changer’, say scientists
Telegraph.co.uk Oncologists at Johns Hopkins University and the Memorial Sloan Kettering Cancer Center administered the immunotherapy drug nivolumab over several weeks to 21 patients with non-small-cell lung cancer prior to surgery. They found the strategy was not … |